Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $33.24 USD
Change Today +0.13 / 0.39%
Volume 317.1K
RLYP On Other Exchanges
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

relypsa inc (RLYP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $42.26
52 Week Low
10/15/14 - $17.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RELYPSA INC (RLYP)

Related News

No related news articles were found.

relypsa inc (RLYP) Related Businessweek News

No Related Businessweek News Found

relypsa inc (RLYP) Details

Relypsa, Inc., a biopharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. Its lead product candidate includes Patiromer, a non-absorbed potassium binding polymer that completed Phase III clinical trial for the treatment of hyperkalemia. The company was founded in 2007 and is based in Redwood City, California.

145 Employees
Last Reported Date: 05/7/15
Founded in 2007

relypsa inc (RLYP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $540.1K
Total Annual Compensation: $172.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $321.9K
Senior Vice President of Pharmaceutical Devel...
Total Annual Compensation: $304.0K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $170.8K
Compensation as of Fiscal Year 2014.

relypsa inc (RLYP) Key Developments

Relypsa Inc. Announces One-Year data from Phase 2 AMETHYST-DN Trial of Patiromer for Oral Suspension

Relypsa Inc. announced that one-year data from the Phase 2 AMETHYST-DN trial of Patiromer for Oral Suspension (Patiromer FOS). Results showed that patients with chronic kidney disease (CKD) and mild or moderate hyperkalemia who were treated with Patiromer FOS had statistically significant decreases in blood potassium levels from baseline at four weeks (p<0.001; primary endpoint). Patiromer FOS quickly reduced potassium levels, with significant reductions at the first post baseline assessment, approximately 48 hours after treatment started (p<0.001). Patients maintained normal blood potassium levels through 52 weeks of treatment. Patiromer FOS was well tolerated when taken for up to one year. All patients had CKD, type 2 diabetes and were taking renin-angiotensin-aldosterone-system (RAAS) inhibitors prior to and during study treatment.

Relypsa, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 01:00 PM

Relypsa, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 01:00 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: John A. Orwin, Chief Executive Officer, President and Director.

Relypsa, Inc. Amends and Restates Amended and Restated Bylaws

On June 4, 2015, in connection with its periodic review of the corporate governance documents of Relypsa, Inc., the company's Board of Directors amended and restated the company's Amended and Restated Bylaws, effective immediately. The Bylaws were amended to: (1) conform the Bylaws to the company's Amended and Restated Certificate of Incorporation with regard to removal of directors by stockholders (Article III, Section 3.11); (2) permit special meetings of committees of the Board to be called by the chairperson of the applicable committee (Article IV, Section 4.3 (ii)); (3) provide that the Board may adopt rules for the governance of any committee of the Board to override the provisions that would otherwise apply to the committee (Article IV, new Section 4.3 (iv)); (4) add the chief executive officer, or any other person authorized by the chief executive officer, to the list of individuals authorized to vote, represent and exercise on behalf of the company all rights incident to any and all shares of any other corporations or corporations standing in the name of the company (Article V, Section 5.6); and (5) include the defined term Voting Stock in Article X.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RLYP:US $33.24 USD +0.13

RLYP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RLYP.
View Industry Companies

Industry Analysis


Industry Average

Valuation RLYP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RELYPSA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at